Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Morf save search
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
Published: 2023-09-22 (Crawled : 21:00) - globenewswire.com
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
| Email alert
Add to watchlist
morf-057 positive
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
Published: 2023-04-25 (Crawled : 12:00) - biospace.com/
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
|
| O: 26.01%
H: 0.22%
C: -14.86%
morf-057 positive topline results
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
Published: 2022-10-25 (Crawled : 20:00) - globenewswire.com
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
|
| O: -0.04%
H: 5.26%
C: 3.81%
morf-057 meeting positive phase 1
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
Published: 2022-10-10 (Crawled : 13:20) - biospace.com/
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
|
| O: -0.71%
H: 0.6%
C: -1.07%
morf-057 week positive phase 1
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
Published: 2022-02-22 (Crawled : 00:00) - globenewswire.com
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
|
| O: -1.4%
H: 8.09%
C: 5.15%
morf-057 presentation positive
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
Published: 2021-07-09 (Crawled : 11:00) - globenewswire.com
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
|
| O: 1.18%
H: 5.52%
C: 5.13%
phase 1 positive phase 2 phase 3
Morphic Therapeutic to Host Analyst and Investor Call on July 9, 2021Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021 Virtual Congress
Published: 2021-07-02 (Crawled : 16:00) - biospace.com/
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
|
| O: -0.82%
H: 3.11%
C: 1.84%
positive results phase 1 positive results trial
Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO’21 Virtual Congress
Published: 2021-05-28 (Crawled : 12:15) - globenewswire.com
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
|
| O: 1.57%
H: 1.02%
C: -2.49%
phase 1 positive phase 3 phase 2
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.9 0.18% 0.18% 460K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.